MPG.eBooks - Description: CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited)

Cover Image

Read Now

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) indication : treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features

The CADTH Canadian Drug Expert Committee (CDEC) recommends that ocrelizumab be reimbursed for the treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2017, November 21, 2017
Edition:	Version 1.0
Series:	CADTH common drug review
Subjects:	Insurance, Health, Reimbursement Antibodies, Monoclonal, Humanized / Economics Multiple Sclerosis, Relapsing-remitting / Drug Therapy Canada Immunologic Factors / Therapeutic Use Cost-benefit Analysis Antibodies, Monoclonal, Humanized / Therapeutic Use
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK534395
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that ocrelizumab be reimbursed for the treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features
Item Description:	"Final."
Physical Description:	1 PDF file (8 pages)